Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
For the full year, revenue was USD 131.31 million compared to USD 196.25 million a year ago. Net income was USD 52.15 million compared to net loss of USD 33.36 million a year ago. Basic earnings per share from continuing operations was USD 3.11 compared to basic loss per share from continuing operations of USD 0.31 a year ago. Diluted earnings per share from continuing operations was USD 3.03 compared to diluted loss per share from continuing operations of USD 0.31 a year ago. Basic earnings per share was USD 3.02 compared to basic loss per share of USD 1.98 a year ago. Diluted earnings per share was USD 2.94 compared to diluted loss per share of USD 1.98 a year ago.